Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Dr. Reddy's Laboratories Ltd. Share Price
Day's Range
Day's Range
Low
₹1,303.60
High
₹1,344.90
Price Summary
| Previous Close | ₹1,336.70 |
|---|---|
| Day's Range | ₹1,303.60 - ₹1,344.90 |
| Open | ₹1,303.60 |
| 52 Week Range | ₹1,148.40 - ₹1,379.70 |
| Volume | 39,82,549 |
| Market Cap | ₹0.11 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 52,842.14 |
|---|---|
| Market Cap (₹ in Mn) | 0.11 |
| Dividend Yield(%) | 0.60 |
| Price/Earning (TTM) | 26.59 |
| TTM EPS (₹) | 50.27 |
| P/E Ratio | 16.87 |
| Book Value(₹) | 2.95 |
| PAT Margin (%) | 17.54 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 23.25 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 55629.0 | 326439.0 |
| Expenses | N/A | N/A |
| PBT | 15618.0 | 76795.0 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 12007.0 | 57252.0 |
About Dr. Reddy's Laboratories Ltd.
| Founded | 1984 |
|---|---|
| Managing Director | GV Prasad |
| NSE Symbol | DRREDDY |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,51,074.97 | 1,879.90 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,79,485.96 | 6,755.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,49,124.14 | 4,386.00 | 3,102.00 - 3,102.00 |
| Apollo Hospitals Enterprise Ltd. | 1,16,201.01 | 8,077.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,15,640.69 | 1,431.55 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,11,589.46 | 1,336.95 | 1,148.40 - 1,148.40 |
| Lupin Ltd. | 1,03,966.32 | 2,273.90 | 1,836.80 - 1,836.80 |
| Mankind Pharma Ltd. | 1,03,368.09 | 2,507.00 | 1,909.70 - 1,909.70 |
| Max Healthcare Institute Ltd. | 1,02,190.60 | 1,050.05 | 903.00 - 903.00 |
| Zydus Lifesciences Ltd. | 1,01,755.41 | 1,011.25 | 835.50 - 835.50 |
No Records Found
Latest News
Dr. Reddy’s Laboratories informs about press release
Dr. Reddy’s Laboratories informs about updates
Dr. Reddy’s Laboratories has informed that the company (‘Dr. Reddy’s’) has on April 29, 2026, received a Notice of Compliance (i.e. an approval) from the Pharmaceutical Drugs Directorate, Canada (‘Health Canada’) regarding its Abbreviated New Drug Submission (ANDS) of Semaglutide Injection. The relevant details as required under Regulation 30 of the SEBI Listing Regulations read with the SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are enclosed. A press release being issued in relation to the above matter is also enclosed.
The above information is a part of company’s filings submitted to BSE.
Dr. Reddy’s Laboratories informs about clarification on news item
With reference to Regulation 30(11) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’) regarding a news item appearing in ‘https://www.cnbctv18.com/’dated April 23, 2026 captioned ‘Dr. Reddy's Laboratories still awaiting approval for a major near-term trigger, sources say’. In this connection, Dr. Reddy’s Laboratories has informed that the above captioned news item headline is correct, as the Company has not yet received approval (‘Notice of Compliance’) for its Semaglutide Injection from Health Canada. Further it has informed that as part of the regulatory review process, the Company has received the ‘Drug Identification Numbers (DINs)’ for Semaglutide Injection from Health Canada on April 22, 2026. The company continue to engage constructively with the regulatory authority and remain committed to bringing the product to the Canadian market upon approval. In compliance with Regulation 30 of the SEBI Listing Regulations, the Company makes prompt disclosures, as and when any event or information is considered material or warrants such disclosure under the said Regulations. The company has informed that at this stage there is no material event/ information that requires disclosure under Regulation 30 of the SEBI Listing Regulations.
The above information is a part of company’s filings submitted to BSE.
Dr. Reddy’s Laboratories informs about compliances certificate
Pursuant to Regulation 74(5) of the SEBI (Depositories and Participants), Dr. Reddy’s Laboratories has enclosed herewith a Confirmation Certificate received from the Registrar and Share Transfer Agent i.e. M/s. Bigshare Services Private Limited for the quarter ended March 31, 2026.
The above information is a part of company’s filings submitted to BSE.
Dr Reddys Laboratories informs about press release
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Dr. Reddy's Laboratories Ltd. is ₹1,336.70 as of 2026-05-15.
The market capitalisation of Dr. Reddy's Laboratories Ltd. is ₹111,589.46 as of 2026-05-15.
The 1-year return of Dr. Reddy's Laboratories Ltd. is 0.00% as of 2026-05-15.
The P/E ratio of Dr. Reddy's Laboratories Ltd. is 16.87 as of 2026-05-17.
The 52-week high and low of Dr. Reddy's Laboratories Ltd. are ₹1,379.70 and ₹1,148.40, respectively, as of 2026-05-15.
People Also Ask
Dr. Reddy's manufactures innovative immunotherapy drug (Zytorvi – PD-1 monoclonal antibody), generic pharmaceuticals (Abiraterone, Dasatinib, Imatinib for oncology; Pregabalin, Teriflunomide for specialty therapies), antibiotics (Daptomycin, Ciprofloxacin), pain management drugs. Global operations, multi-therapeutic portfolio spanning oncology, immunology, cardiology, neurology segments.
Dr. Reddy's collaborates with hospital networks for clinical trials, healthcare providers for treatment protocols, research institutions for drug development, global pharmaceutical partners for commercialisation, patient assistance programs through healthcare partnerships, and supply chain integration with dispensary networks ensuring drug accessibility nationwide.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
